학술논문

The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations
Document Type
article
Source
American Journal of Human Genetics. 103(3)
Subject
Biological Sciences
Biomedical and Clinical Sciences
Genetics
Health Services and Systems
Health Sciences
Clinical Sciences
Clinical Research
Human Genome
Health Services
Biotechnology
Aetiology
2.1 Biological and endogenous factors
Generic health relevance
Good Health and Well Being
Adult
Cost-Benefit Analysis
Delivery of Health Care
Europe
Exome
Genome
Human
Genomics
Humans
National Human Genome Research Institute (U.S.)
Phenotype
United States
Whole Genome Sequencing
CSER consortium
Medical and Health Sciences
Genetics & Heredity
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
The Clinical Sequencing Evidence-Generating Research (CSER) consortium, now in its second funding cycle, is investigating the effectiveness of integrating genomic (exome or genome) sequencing into the clinical care of diverse and medically underserved individuals in a variety of healthcare settings and disease states. The consortium comprises a coordinating center, six funded extramural clinical projects, and an ongoing National Human Genome Research Institute (NHGRI) intramural project. Collectively, these projects aim to enroll and sequence over 6,100 participants in four years. At least 60% of participants will be of non-European ancestry or from underserved settings, with the goal of diversifying the populations that are providing an evidence base for genomic medicine. Five of the six clinical projects are enrolling pediatric patients with various phenotypes. One of these five projects is also enrolling couples whose fetus has a structural anomaly, and the sixth project is enrolling adults at risk for hereditary cancer. The ongoing NHGRI intramural project has enrolled primarily healthy adults. Goals of the consortium include assessing the clinical utility of genomic sequencing, exploring medical follow up and cascade testing of relatives, and evaluating patient-provider-laboratory level interactions that influence the use of this technology. The findings from the CSER consortium will offer patients, healthcare systems, and policymakers a clearer understanding of the opportunities and challenges of providing genomic medicine in diverse populations and settings, and contribute evidence toward developing best practices for the delivery of clinically useful and cost-effective genomic sequencing in diverse healthcare settings.